Goecyst-M Tablet SR is a sustained-release oral formulation combining Metformin 500 mg and Myo-Inositol 600 mg, designed to manage metabolic and endocrine disorders, particularly in patients with insulin resistance and polycystic ovary syndrome (PCOS). Metformin, a biguanide antihyperglycemic agent, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity, thereby aiding in glycemic control in type 2 diabetes mellitus. Myo-Inositol, a naturally occurring isomer of inositol, plays a crucial role in cellular signaling and insulin signal transduction, contributing to improved ovarian function and hormonal balance. The synergistic action of these two components helps in reducing insulin resistance, restoring ovulatory cycles, and improving metabolic parameters such as lipid profiles and body mass index. Goecyst-M Tablet SR’s sustained-release formulation ensures a gradual release of active ingredients, minimizing gastrointestinal side effects commonly associated with Metformin and enhancing patient compliance. This combination is particularly beneficial for women with PCOS who exhibit insulin resistance and require both metabolic and reproductive system support. It is recommended to be used under medical supervision, with dosage adjustments based on clinical response and tolerability. Regular monitoring of blood glucose and renal function is advised during therapy.